Aledade has raised $30 million in funding. ARCH Venture Partners led the round with participation from Venrock. Based in Bethesda, Maryland, Aledade helps doctors form and operate accountable care organizations. To read the post, visit here.
Rockville, Maryland-based Regenxbio, a gene therapy-focused biotech company, has closed $70.5 million in Series D funding. Vivo Capital, Venrock and Brookside Capital led the round with participation from other investors that included Janus Capital Management LLC, Perceptive Advisors LLC, Tourbillon Global Ventures, Sectoral Asset Management, Cormorant Asset Management LLC, Foresite Capital Management, Deerfield Management and Fidelity Biosciences. Chardan Capital Markets LLC was the placement agent.
Spirox Inc. said Monday it closed an $18.5 million Series B round of financing led by Venrock and Aisling Capital. Existing investors Aperture Venture Partners, Correlation Ventures and Western Technology Investment also participated in the round. Menlo Park, California-based Spirox is a medical device company focused on developing minimally invasive technologies to treat nasal obstruction.
Berkeley Heights, New Jersey-based Edge Therapeutics, a biotech company focused on developing therapies for neurological conditions, has secured about $72.5 million in funding from two recent rounds. The company just closed $56 million in a Series C-2 funding round led by Venrock with participation from other investors that included Sofinnova Ventures, Janus Capital Management LLC, New Leaf Venture Partners and BioMed Ventures. The earlier round, which closed in December 2014, raised $16.5 million in Series C-1 funding. The investors for that round were not named. In connection to the Series C-2 round, Dr. Anders Hove of Venrock and Dr. James Healy, a managing partner at Sofinnova Ventures, have been added to Edge Therapeutics’ board of directors.
Sunnyvale, California-based Niara, a stealth security startup, has raised $20 million in Series B funding. Venrock led the round with participation from other investors that included New Enterprise Associates and Index Ventures. In conjunction with the funding, Doug Dooley of Venrock has been appointed to Niara’s board of directors.
RedSeal, a cybersecurity analytics platform provider, has relaunched with $17 million in Series C funding. The investors included Tyco, MATH Venture Partners, Pallasite Ventures, DRW, Venrock, Sutter Hill, Icon Ventures, Leapfrog and Olympic Ventures.
Aeglea Biotherapeutics Inc, a biopharmaceutical company focused on treating tumor metabolism, has raised $44 million in Series B funding. Return backers Lilly Ventures and Novartis Venture Fund led the round with participation from other investors that included UT Horizon Fund, OrbiMed, Jennison Associates (on behalf of clients), Venrock, RA Capital Management, Rock Springs Capital, Ally Bridge Group and Cowen Investments.
Dataminr, a real-time information discovery company, has secured $130 million in funding. Fidelity Management & Research Company led the round with participation from other investors that included Wellington Management Company LLP, Credit Suisse NEXT Investors, Venrock and Institutional Venture Partners.
San Francisco-based on-demand parking service Luxe has received $20 million in Series A funding. The investors were Venrock and Redpoint Ventures. In addition to the funding, Brian Ascher of Venrock and Ryan Sarver of Redpoint Ventures have been appointed to Luxe’s board of directors. Also, Luxe has hired Ro Choy as chief business officer.
Bain Capital Ventures has led a $20 million Series B funding round in 6sense, a SaaS-based predictive intelligence platform for marketing and sales. Previous investors Battery Ventures and Venrock also participated in the round. The deal is the first for Indy Guha since he was promoted to partner at Bain Capital Ventures last week. As part of the funding, he will join the board of 6sense. The funding brings the total financing to $36 million for the San Francisco-based company.
Danish biotech firm Ascendis Pharma has raised $108 million for its IPO after pricing its 6 million shares at $18 per share. The stock begins trading Wednesday on the NASDAQ under the ticker symbol “ASND.” BofA Merrill Lynch and Leerink Partners are serving as the lead underwriters. Ascendis Pharma’s backers include Sofinnova Ventures, OrbiMed, Vivo Capital, Venrock, RA Capital Management and Janus Capital Management.
Marketing intelligence software provider Beckon has raised $13 million in Series B funding. Venrock led the round with participation from other investors that included August Capital, Canaan Partners and El Dorado Ventures.
Regenxbio, a gene therapy biotech firm, has closed $30 million in Series C funding. Venrock and Brookside Capital led the round with participation from others investors that included Deerfield Management, FoxKiser and Fidelity BioSciences. Also, Camille Samuels, a partner at Venrock and Michael Gelman have been added to Regenxbio’s board of directors.
Pleasanton, California-based 10X Genomics, a genomics platform provider, has closed $55.5 million in Series B funding. Foresite Capital Management led the round with participation from other investors that included Venrock, Paladin Capital Group and Morgan Stanley Investment Management.
Juno Therapeutics has debuted its IPO after pricing its over 11 million shares at $24 per share. The stock began trading Friday on the NASDAQ under the ticker symbol “JUNO.” Morgan Stanley, J.P. Morgan Securities and Goldman Sachs are the lead underwriters. Based in Seattle, Juno is a biotech company focused on developing immunotherapies for cancer. Its backers include Bezos Expeditions, Venrock, ARCH Venture Partners and the Alaska Permanent Fund.
Phononic has closed $44.5 million in Series D funding. Eastwood Capital Corp and the Wellcome Trust led the round with participation from WLR China Energy Infrastructure Fund, Tsing Capital, Venrock, Oak Investment Partners and Rex Health Ventures. Headquartered in Research Triangle Park, North Carolina, Phononic is a provider of solid state thermal management solutions.
Acceleron Pharma has appointed Dr. Francois Nader to its board of directors. Nader is president, CEO and a member of the board of directors of NPS Pharma. Acceleron Pharma’s backers include Advanced Technology Ventures, Flagship Ventures, OrbiMed Advisors, Polaris Ventures and Venrock. Based in Cambridge, Mass., Acceleron is focused on developing novel protein therapeutics for cancer and rare diseases.
San Francisco-based biotech firm Audentes Therapeutics has secured $42.5 million in Series B financing. Deerfield Management led the round with participation from Sofinnova Ventures, Venrock, OrbiMed, 5AM Ventures and Versant Ventures. As a result of the transaction, Jonathan Leff, a partner at Deerfield, will join Audentes’ board of directors.